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ABSTRACT
Objective: 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
or statins, have been associated with improved clinical outcomes after ischemic stroke 
and subarachnoid hemorrhage, but with an increased risk of incidental spontaneous 
intracerebral hemorrhage (ICH). We investigated whether the statin use before ICH, was 
associated with functional independence, 90 days after treatment. Method: We analyzed 
124 consecutive ICH patients with 90-day outcome data who were enrolled in a prospective 
cohort study between 2006 and 2009. Eighty-three patients were included in this study. 
Among ICH survivors, univariate Cox regression models and Kaplan-Meier plots were 
used to determine subject characteristics that were associated with an increased risk of 
recurrence. Statin usage was determined through interviewing the patient at the time of 
ICH and confirmed by reviewing their medical records. Independent status was defined 
as Glasgow Outcome Scale grades 4 or 5. Results: Were stain users 20/83 (24%) patients 
before the ICH. There was no effect from pre-ICH statin use on the functional independence 
rates (32% versus 36%, P=0.79) or mortality (41% versus 47%, P=0.82). Conclusion: 
Pre-ICH statin use is not associated with changes to ICH functional outcome or mortality. 
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estatinas
RESUMO
Objetivo: Inibidores da 3-hydroxy-3-methylglutaryl coenzima A (HMG-CoA) redutase, 
ou estatinas, têm sido associados com melhora do prognóstico após eventos encefálicos 
isquêmicos e hemorragia subaracnóidea, mas com um aumento do risco de evento 
encefálico hemorrágico (AVEh). Nós investigamos se o uso de estatinas prévio ao 
sangramento é associado com independência funcional em 90 dias. Método: Analisamos 
124 pacientes consecutivos com AVEh com 90 dias de seguimento, selecionando 83 para 
um estudo coorte prospectivo entre 2006 e 2009. O uso de estatinas foi determinado pela 
entrevista ao paciente no momento da entrada ao hospital e complementado pela revisão 
do prontuário. Foi definido como independência funcional um GOS (Glasgow Outcome 
Scale) 4 ou 5. Resultados: Estatinas eram usadas por 20/83 (24%) antes do AVEh. Não 
houve efeito benéfico do uso prévio ao AVEh de estatinas nas taxas de independência 
funcional (32% versus 36%, P=0,79) ou mortalidade (41% versus 47%, P=0,82). Conclusão: 
O uso de estatina pré-AVEh não é associado com melhora do prognóstico funcional ou 
taxa de mortalidade.
Palavras-chave: hemorragia cerebral, inibidores de hidroximetilglutaril-CoA redutases.
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Intracerebral hemorrhage (ICH) causes first-time 
stroke in 10% to 15% of such patients, with a 30-day mor-
tality rate of 35% to 52%; half of the deaths occur in the 
first two days1-3. In one population study on 1041 cases of 
ICH, 50% had a deep location, 35% were lobar, 10% were 
cerebellar and 6% were in the brain stem4. e mortality 
rate one year after ICH varies according to the location 
of the ICH: 51% for deep hemorrhage, 57% for lobar, 42% 
for cerebellar and 65% for brain stem5. Out of the esti-
mated 67,000 patients who had an ICH in the United 
States during 2002, only 20% are expected to be func-
tionally independent six months later3.
3-hydroxy-3-methylglutaryl coenzyme A (HMG-
CoA) reductase inhibitors, or statins, have other effects 
in addition to decreasing cholesterol synthesis6. Statin-
treated animals have better outcomes in experimental 
models for ischemic stroke7 and intracerebral hemor-
rhage (ICH)8,9. Human studies suggest that statins are 
associated with better outcomes after ischemic stroke10 
and subarachnoid hemorrhage11.
In contrast, it is not known whether pre-ICH statin 
use confers better outcomes among patients with ICH. 
Some of the pleiotropic effects of statins, such as de-
creased platelet aggregation12 and decreased thrombo-
genesis13, may promote hematoma expansion or increase 
the risk of recurrent hemorrhage.
erefore, we investigated whether prior use of statin 
would improve the outcome among patients with ICH.
METHOD
We retrospectively analyzed data from an ongoing 
single-center prospective longitudinal cohort study on 
primary ICH. All patients with a baseline admission CT 
scan and determination of functional status at 90 days 
were eligible. Clinical information, including medica-
tion use and dosage, was abstracted from the medical 
records and supplemented by interview. ICH volume 
and location were determined by means of computer-
assisted segmentation. is study was approved by the 
local ethics committee.
There were 124 consecutive admissions with 
symptom onset between January 1, 2006 and December 
31, 2010. Baseline CT scan was not performed or was 
missing in 8/124 (0.6%), and other data were missing in 
5/124 (0.4%), leaving 111 subjects with complete baseline 
information. Death within 30 days occurred in 28/111, 
thus leaving 83/111 30-day survivors. erefore, 90-day 
Glasgow outcome scale (GOS) was determined for a 
total of 83/124 potential subjects (67%).
Independent status was defined as GOS 4 or 5. Lo-
gistic regression models were constructed to determine 
whether pre-ICH statin use was associated with inde-
pendent status or mortality. Age and Glasgow coma 
score (GCS) score were categorized according to cutoff 
points that were established in univariate analysis, as fol-
lows: [1] age: <69, 70 to 79 and >80, [2] GCS: 3 to 10, 11 
to 14 and 15. 
Among the ICH survivors, univariate Cox regression 
models and Kaplan-Meier plots were used to determine 
subject characteristics that were associated with an in-
creased risk of recurrence. Post-ICH statin use was an-
alyzed as a time-dependent variable because some sub-
jects started or discontinued statins during the follow-up 
period. Post-ICH statin use and any variables associated 
with ICH recurrence (P<0.20) were entered into a mul-
tivariable Cox regression model, followed by backward 
elimination of nonsignificant variables (P>0.05). Statis-
tical analyses were performed using SAS version 9.1.3. 
RESULTS
Were statin users 20/83 (24%) patients before the 
ICH. ere was no effect from pre-ICH statin use on the 
functional independence rates (32% versus 36%, P=0.79) 
or mortality (41% versus 47%, P=0.82). Medical comor-
bidities and warfarin use were more common in statin 
users. e multivariable-adjusted odds ratio for indepen-
dent status in pre-ICH statin users was 1.03 (95% CI: 0.71 
to 2.21, P=0.71).
Pre-ICH statin use was not associated with indepen-
dent status or mortality (Table). We considered whether 
the effect of statin use might vary according to outcome 
definition or patient subgroups. ere was no difference 
in 30-day or 90-day survival in pre-ICH statin users 
(data not shown). Because statin withdrawal may worsen 
stroke outcome14,15, we performed additional analyses 
after subtracting subjects among whom statins were 
discontinued (n=12) or adding subjects among whom 
statins were started (n=15). However, the sample did not 
have enough power to allow definitive conclusions.
DISCUSSION
e initial experimental evidence generated from an-
imals appeared in a couple of studies in 2004. In one 
Table. Some data from the patients according to presence of 
statin use before ICH.
Characteristic
Statin n=20 
(24%)
No statin 
n=63 (76%) P
Median age (SD) 68 (8.2) 69 (7.6) 0.73
GCS (variation) 11 (6-15) 12 (6-15) 0.89
GOS 4 or 5
(90-day independence)
32% 36% 0.79
90-day mortality 41% 47% 0.82
GCS: Glasgow coma scale; GOS: Glasgow outcome scale.
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of them, atorvastatin was administered orally beginning 
24 h after ICH and was continued daily for one week. 
With a low dose of 2 mg/kg, a significant reduction in 
neurological deficit two to four weeks after the ICH was 
observed, while a higher dose of 8 mg/kg did not im-
prove functional outcome or reduce the brain damage14.
Supported by these studies, initial attempts to eval-
uate the effect on humans were made. In a retrospective 
study performed at Johns Hopkins Hospital, the effect 
of statin administered prior to ICH was assessed among 
125 consecutive ICH patients. e authors found that 
patients with prior statin use had less perifocal edema 
than did those without prior statin use. e multivar-
iate analysis showed a significant correlation between 
prior statin use and reduction of early absolute edema 
volume15. e same group demonstrated that prior use 
of statins was associated with lower mortality at 30 days.
We did not detect any difference in outcomes among 
patients taking statins before ICH, even after adjustment 
for medical comorbidities. In contrast, treatment with 
statins improved sensorimotor recovery in two animal 
models for ICH8,9. However, there may be biological dif-
ferences between animals and humans regarding the type 
of injury that occurs after ICH. In contrast to the animal 
studies, our subjects were taking various types and doses 
of statins. A recent study suggested that statins are as-
sociated with decreased 30-day mortality but not with 
improved functional outcome16,17. In our study, pre-ICH 
statin use had no effect on 30-day mortality. It is un-
clear whether the different results occurred because of 
the play of chance, or because of differences in the pop-
ulations studied.
e main limitation of our study is that statin use was 
not randomly assigned, and therefore associations be-
tween statins and either ICH outcomes or recurrent ICH 
may be confounded with other factors that are associated 
with statin use, even though we adjusted for recognized 
confounders using regression models.
Our analysis of the dose-response effect of statins 
on ICH outcomes uses the simplistic assumption that 
maximum dose strengths are equipotent across different 
drugs.
ese data come from a not-so-large series of con-
secutive ICH cases with functional outcome data and 
prospective follow-up and therefore provide a best esti-
mate of the effect of statins on ICH outcomes in the ab-
sence of large trials. FitzMaurice calculated that a trial of 
statins to improve 90-day outcome should include 1026 
subjects (randomized 1:1 to treat with statin or placebo), 
for it to get 90% power to detect an OR >1.24, for inde-
pendent status in the statin arm18.
It is too early to come to any conclusion. In addition, 
because of the small sample size of the present study, and 
because the underlying prospective study does not de-
fine the statins that were used, no definitive conclusion 
can be drawn until a comprehensive, double blind, pro-
spective study is performed.
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Dear Editors,
Ref. Article: Romero FR, Bertolini E, Velozo VN, Venturini L, Figueiredo 
EG. Outcomes from intracerebral hemorrhage among patients pre-
treated with statins. Arq Neuropsiquiatr 2011;69:452-454.
Some similar points have been observed between our paper and other 
by FitzMaurice et al. Effect of Statins on Intracerebral Hemorrhage Outcome 
and Recurrence. Stroke 2008; 39:2151-2154. These points are not coincidental 
but resulted from mistakes when the documents were  selected and sent to 
the editor. So, instead of selecting my own results, I sent a file with graphic 
and words containing the data from the table of the Fitz Maurice’s paper from 
which I intended to compare my data and present my results. Consequentely, 
my data have not been published but just the Fitz Maurice’s  results have 
been displayed as they were mine. I take the total responsibility about this 
oversight. The Department of Neurology, the Division of Neurosurgery and 
the Post Graduation program of the University of São Paulo and their person-
nel have no responsibility for this inaccuracy, as this article was designed and 
developed in other institution. 
I would like to convey my regrets and apologies about this inopportune 
misunderstanding. Should I had been more meticulous in my revision of the 
documents before sending them and when I received the proofs, it would 
have not occurred. The Stroke paper was the initial inspiration for my work 
and it was actually used as reference that I now would like to include. I pres-
ent a new table displaying my actual data and revision of the text to replace 
that that was portrayed before. 
Replace Table 1 for the following:
Table 1. Some data from the patients according to presence of 
statin use before ICH.
Characteristic Statin n=20 (24%) No statin n=63 (76%) P
Median age (SD) 68 (8.2) 69 (7.6) 0.73
GCS (variation) 11 (6-15) 12 (6-15) 0.89
GOS 4 or 5 (90-day 
independence) 32% 36% 0.79
90-day mortality 41% 47% 0.82
In the sentence:
“We calculated that a trial of statins to improve …
Change to:
FitzMaurice calculated that a trial of statins to improve 90-day outcome 
should include 1026 subjects (randomized 1:1 to treat with statin or placebo), 
for it to get 90% power to detect an OR >1.24, for independent status in the 
statin arm18.
In the sentence:
“Statins were used …
Change to:
Were statin users 20/83 (24%) patients before the ICH. There was no 
effect from pre-ICH statin use on the functional independence rates (32% 
versus 36%, P=0.79) or mortality (41% versus 47%, P=0.82). Medical comor-
bidities and warfarin use were more common in statin users. The multivari-
able-adjusted odds ratio for independent status in pre-ICH statin users was 
1.03 (95% CI: 0.71 to 2.21, P=0.71).
Include a new reference:
18. FitzMaurice E, Wendell L, Snider R, et al. Effect of Statins on Intracerebral 
Hemorrhage Outcome and Recurrence. Stroke 2008; 39:2151-2154.
Best regards,
Flávio Ramalho Romero
